Excessive or aberrant activity of specific proteins like BCL6 and cardiac myosin leads to disease progression. Reducing these protein levels or modulating their activity prevents cellular dysfunction and organ failure.

Inadequate recruitment and stimulation of natural killer cells and multispecific antibodies limits the body's ability to clear malignant cells. Overcoming this immune evasion is critical for treating myeloid disorders and acute leukemias.

Uncontrolled viral replication and high pathogenicity lead to severe disease outcomes. Reducing virulence through attenuation or entry inhibition prevents host damage and enables safe vaccine development.

Aberrant signaling from mutated RAS and PLK1 proteins drives unchecked tumor growth and metastasis. Mitigating these drivers prevents therapeutic resistance and disease progression.

Insufficient precision in identifying or modifying genetic and antigenic markers prevents effective disease neutralization. Enhancing targeting accuracy enables the immune system to recognize and eliminate specific pathological cells or transcripts.

Insufficient natural defense mechanisms against pathogenic colonization and systemic vascular complications. Enhancing targeted immune activation prevents severe infectious and thromboembolic morbidity.